0001562180-15-000533.txt : 20150630
0001562180-15-000533.hdr.sgml : 20150630
20150630164847
ACCESSION NUMBER: 0001562180-15-000533
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150626
FILED AS OF DATE: 20150630
DATE AS OF CHANGE: 20150630
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tokai Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001404281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 255 STATE STREET
STREET 2: 6TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: 617-225-4348
MAIL ADDRESS:
STREET 1: 255 STATE STREET
STREET 2: 6TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Morrison Jodie Pope
CENTRAL INDEX KEY: 0001618247
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36620
FILM NUMBER: 15961876
MAIL ADDRESS:
STREET 1: C/O TOKAI PHARMACEUTICALS, INC.
STREET 2: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2015-06-26
false
0001404281
Tokai Pharmaceuticals Inc
TKAI
0001618247
Morrison Jodie Pope
C/O TOKAI PHARMACEUTICALS, INC.
255 STATE STREET, 6TH FLOOR
BOSTON
MA
02109
true
true
false
false
President and CEO
Common Stock
2015-06-26
4
M
false
8000.00
1.58
A
17551.00
D
Common Stock
2015-06-26
4
S
false
8000.00
13.83
D
9551.00
D
Common Stock
2015-06-29
4
M
false
8000.00
1.58
A
17551.00
D
Common Stock
2015-06-29
4
S
false
8000.00
13.70
D
9551.00
D
Stock Option (right to buy)
1.58
2015-06-26
4
M
false
8000.00
0.00
D
2023-06-26
Common Stock
8000.00
333300.00
D
Stock Option (right to buy)
1.58
2015-06-29
4
M
false
8000.00
0.00
D
2023-06-26
Common Stock
8000.00
325300.00
D
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.70 to $14.125 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.70 to $13.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option was granted on June 26, 2013. With respect to 258,825 shares underlying the option, 2.0833% of those shares vested on July 1, 2013 and an additional 2.0833% of those shares vest on the first day of each month thereafter through June 1, 2017. With respect to 82,475 shares underlying the option, 8.333% of those shares vested on October 24, 2013 and an additional 2.0833% of those shares vest on the first day of each month thereafter through June 1, 2017. Upon the closing of the Issuers initial public offering in September 2014, the vesting for this option accelerated by 12 months.
/s/ Cindy Driscoll, Attorney-in-Fact
2015-06-30